Research Discovers That Switching to Infliximab Biosimilar Is Safe and Helpful for IBD Patients.

Published Date: 26 Oct 2023

According to recent research, switching from biosimilar CT-P13 to SB2 is safe and effective. Throughout the 12-month follow-up, there were no appreciable changes in the psychometric assessments of the study participants.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot